The figitumumab combination appeared more toxic , with more treatment-related grade @/@ adverse events ( @ % vs. @ % ) , particularly hyperglycemia , diarrhea , and asthenia , as well as treatment-related serious adverse events ( @ % vs. @ % ) , and all-causality grade @ adverse events ( @ % vs. @ % ) .